person · Reporting owner

BAYER AKTIENGESELLSCHAFT

Disclosed activity across 7 companies

Tapewire entity: 82089
SEC CIK: 0001144145

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Azitra, Inc.AZTR · Entity 7959	10% owner	June 21, 2023	July 24, 2023
CRISPR Therapeutics AGCRSP · Entity 3852	10% owner	January 05, 2018	January 30, 2018
Century Therapeutics, Inc.IPSC · Entity 5739	10% owner	June 22, 2021	June 23, 2021
Metagenomi Therapeutics, Inc.MGX · Entity 7270	10% owner	February 13, 2024	February 15, 2024
Senti Biosciences Holdings, Inc.SNTI · Entity 7935	10% owner	March 10, 2025	March 12, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Azitra, Inc.

Report date June 21, 2023 · Filed July 24, 2023

Jointly reported with BAYER HEALTHCARE LLC, Bayer US Holding LP, Bayer World Investments B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,307,401	Reported balance After 2023-06-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-21 · Conversion · Acquired 1,307,401 · Balance 1,307,401 F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-06-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-21 · Conversion · Disposed 1,307,401 · Balance 0 F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date.

F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.

CRISPR Therapeutics AG

Report date January 05, 2018 · Filed January 30, 2018

Jointly reported with Bayer Global Investments B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectBy subsidiary	5,632,802	Reported balance After 2018-01-05 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2018-01-05 · Purchase · Acquired 527,472 · Balance 5,632,802 F1: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner.
Common SharesSEC Table I · non-derivative	IndirectBy subsidiary	75,945	Reported balance Holding disclosure · report date 2018-01-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 75,945 F2: Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner.

F2: Reflects shares of CRISR received by a subsidiary of Bayer AG as a pro rata distribution from a limited partnership. Bayer AG is the 100% Indirect Owner through subsidiaries of such shares.

Century Therapeutics, Inc.

Report date June 22, 2021 · Filed June 23, 2021

Jointly reported with Bayer World Investments B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,675,838	Last balance in matching sequence After 2021-06-22 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2021-06-22 · Conversion · Acquired 10,390,600 · Balance 10,390,600 F1: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Row 2 · 2021-06-22 · Conversion · Acquired 1,535,238 · Balance 11,925,838 F3: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Row 3 · 2021-06-22 · Purchase · Acquired 750,000 · Balance 12,675,838 F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-06-22 · Conversion · Disposed 26,143,790 · Balance 0 F1: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-06-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-06-22 · Conversion · Disposed 3,862,813 · Balance 0 F3: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.

F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

F3: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.

Metagenomi Therapeutics, Inc.

Report date February 13, 2024 · Filed February 15, 2024

Jointly reported with BAYER HEALTHCARE LLC, Bayer US Holding LP, Bayer World Investments B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,050,997	Last balance in matching sequence After 2024-02-13 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2024-02-13 · Conversion · Acquired 1,770,888 · Balance 1,770,888 F1: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Row 2 · 2024-02-13 · Conversion · Acquired 1,180,592 · Balance 2,951,480 F3: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Row 3 · 2024-02-13 · Conversion · Acquired 589,662 · Balance 3,541,142 F4: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Row 4 · 2024-02-13 · Conversion · Acquired 509,855 · Balance 4,050,997 F5: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-13 · Conversion · Disposed 3,093,580 · Balance 0 F1: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series A-4 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-13 · Conversion · Disposed 2,062,387 · Balance 0 F3: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-13 · Conversion · Disposed 1,030,086 · Balance 0 F4: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-13 · Conversion · Disposed 890,671 · Balance 0 F5: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO").

F3: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.

F4: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.

F5: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO.

Senti Biosciences Holdings, Inc.

Report date March 10, 2025 · Filed March 12, 2025

Jointly reported with BAYER HEALTHCARE LLC, Bayer US Holding LP, Bayer World Investments B.V.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,809,848	Reported balance After 2025-03-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-03-10 · Conversion · Acquired 2,222,000 · Balance 2,809,848 F1: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-03-10 · Conversion · Disposed 2,222 · Balance 0 F1: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F3: The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased. F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2029-12-09	Direct	3,330,000	Reported balance Holding disclosure · report date 2025-03-10 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 3,330,000 F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025.

F2: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.

F3: The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Elanco Animal Health Inc

Report date December 03, 2020 · Filed December 03, 2020

Jointly reported with Bayer World Investments B.V.

Section 16 reporting ended · disclosed 2020-12-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	18,446,429	Reported balance After 2020-12-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-12-03 · Sale · Disposed 54,500,000 · Balance 18,446,429 F1: Pursuant to an underwriting agreement, dated November 30, 2020, and in connection with the registered public offering of shares of common stock of the Issuer ("Common Stock") pursuant to the prospectus, dated as of January 21, 2020 and filed with the U.S. Securities and Exchange Commission (the "SEC") on January 21, 2020 and the prospectus supplement dated as of November 30, 2020 and filed with the SEC on December 2, 2020, which offering settled on December 3, 2020, Bayer World Investments B.V. sold 54,500,000 shares of Common Stock. F2: The securities reported as sold were, and those reported as held after the transaction are, held directly by Bayer World Investments B.V., which is an indirect wholly owned subsidiary of Bayer Aktiengesellschaft. Bayer Aktiengesellschaft may be deemed to beneficially own the shares of the Issuer's Common Stock beneficially owned by Bayer World Investments B.V.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an underwriting agreement, dated November 30, 2020, and in connection with the registered public offering of shares of common stock of the Issuer ("Common Stock") pursuant to the prospectus, dated as of January 21, 2020 and filed with the U.S. Securities and Exchange Commission (the "SEC") on January 21, 2020 and the prospectus supplement dated as of November 30, 2020 and filed with the SEC on December 2, 2020, which offering settled on December 3, 2020, Bayer World Investments B.V. sold 54,500,000 shares of Common Stock.

F2: The securities reported as sold were, and those reported as held after the transaction are, held directly by Bayer World Investments B.V., which is an indirect wholly owned subsidiary of Bayer Aktiengesellschaft. Bayer Aktiengesellschaft may be deemed to beneficially own the shares of the Issuer's Common Stock beneficially owned by Bayer World Investments B.V.

Pyxis Oncology, Inc.

Report date October 13, 2021 · Filed October 15, 2021

Jointly reported with Bayer World Investments B.V.

Section 16 reporting ended · disclosed 2021-10-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,742,338	Reported balance After 2021-10-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-10-13 · Conversion · Acquired 2,742,338 · Balance 2,742,338 F1: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-13 · Conversion · Disposed 11,362,462 · Balance 0 F1: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-10-13 · Conversion · Disposed 6,076,072 · Balance 0 F1: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 10, 2025 Filed Mar 12, 2025 20:31 UTC	Senti Biosciences Holdings, Inc. SNTI · Entity 7935	ConversionSeries A Convertible Preferred Stock · Derivative	2,222	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-25-000173 · primary_doc.xml · derivative · entry 2 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,222,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F3 · price: The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F1 · derivative.underlying_shares: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
March 10, 2025 Filed Mar 12, 2025 20:31 UTC	Senti Biosciences Holdings, Inc. SNTI · Entity 7935	ConversionCommon Stock	2,222,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-25-000173 · primary_doc.xml · nonDerivative · entry 1 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,809,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F1 · price: Each share of Series A Convertible Preferred Stock ("Series A") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
December 09, 2024 Filed Dec 11, 2024 19:38 UTC	Senti Biosciences Holdings, Inc. SNTI · Entity 7935	PurchaseWarrant · Derivative	3,333,000	Not disclosed Strike: $2.30	Not disclosed	Disclosure SEC source: 0001578563-24-000493 · primary_doc.xml · derivative · entry 3 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,330,000 Underlying: Common Stock · 3,333,000 shares Expires 2029-12-09 F3 · price: The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased. F4 · derivative.exercise_date: The warrant becomes exercisable once the Issuer's stockholders first approve the issuance of the Issuer's common stock underlying the warrants in excess of the limitations imposed by Rule 5635 of the Nasdaq Stock Market listing rules. F1 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
December 09, 2024 Filed Dec 11, 2024 19:38 UTC	Senti Biosciences Holdings, Inc. SNTI · Entity 7935	PurchaseSeries A Convertible Preferred Stock · Derivative	2,222	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-24-000493 · primary_doc.xml · derivative · entry 2 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,222 Underlying: Common Stock · 2,222,000 shares Expires not disclosed F2 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A. F3 · price: The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased. F2 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A. F2 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A. F2 · derivative.underlying_shares: Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A. F1 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSeries B-1 Convertible Preferred Stock · Derivative	890,671	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · derivative · entry 8 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 509,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F5 · derivative.exercise_date: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F5 · derivative.expiration_date: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSeries B Convertible Preferred Stock · Derivative	1,030,086	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · derivative · entry 7 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 589,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F4 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F4 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSeries A-4 Convertible Preferred Stock · Derivative	2,062,387	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · derivative · entry 6 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,180,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F3 · derivative.exercise_date: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F3 · derivative.expiration_date: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionSeries A-1 Convertible Preferred Stock · Derivative	3,093,580	$0.00	$0.00	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · derivative · entry 5 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,770,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F1 · derivative.exercise_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F1 · derivative.expiration_date: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionCommon Stock	509,855	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · nonDerivative · entry 4 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,050,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionCommon Stock	589,662	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · nonDerivative · entry 3 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,541,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionCommon Stock	1,180,592	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · nonDerivative · entry 2 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,951,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
February 13, 2024 Filed Feb 15, 2024 17:59 UTC	Metagenomi Therapeutics, Inc. MGX · Entity 7270	ConversionCommon Stock	1,770,888	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-24-000080 · primary_doc.xml · nonDerivative · entry 1 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
June 21, 2023 Filed Jul 24, 2023 17:51 UTC	Azitra, Inc. AZTR · Entity 7959	ConversionSeries B Convertible Preferred Stock · Derivative	1,307,401	$0.00	$0.00	Disclosure SEC source: 0001578563-23-000065 · primary_doc.xml · derivative · entry 2 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,307,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
June 21, 2023 Filed Jul 24, 2023 17:51 UTC	Azitra, Inc. AZTR · Entity 7959	ConversionCommon Stock	1,307,401	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-23-000065 · primary_doc.xml · nonDerivative · entry 1 BAYER HEALTHCARE LLC · CIK 0001231517 · 10% owner Bayer US Holding LP · CIK 0001965754 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,307,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. Read SEC document
October 13, 2021 Filed Oct 15, 2021 17:05 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	ConversionSeries B Convertible Preferred Stock · Derivative	6,076,072	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-21-000038 · primary_doc.xml · derivative · entry 3 Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 955,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
October 13, 2021 Filed Oct 15, 2021 17:05 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	ConversionSeries A Convertible Preferred Stock · Derivative	11,362,462	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-21-000038 · primary_doc.xml · derivative · entry 2 Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,786,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · derivative.exercise_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F1 · derivative.expiration_date: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
October 13, 2021 Filed Oct 15, 2021 17:05 UTC	Pyxis Oncology, Inc. PYXS · Entity 5986	ConversionCommon Stock	2,742,338	Not disclosed	Not disclosed	Disclosure SEC source: 0001578563-21-000038 · primary_doc.xml · nonDerivative · entry 1 Bayer World Investments B.V. · CIK 0001820027 · Former 10% Owner BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,742,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
June 22, 2021 Filed Jun 23, 2021 16:41 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	ConversionSeries C Preferred Stock · Derivative	3,862,813	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-042752 · doc4.xml · derivative · entry 5 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,535,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F3 · price: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F3 · derivative.exercise_date: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F3 · derivative.expiration_date: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F3 · derivative.underlying_shares: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
June 22, 2021 Filed Jun 23, 2021 16:41 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	ConversionSeries B Preferred Stock · Derivative	26,143,790	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-042752 · doc4.xml · derivative · entry 4 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,390,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F1 · price: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F1 · derivative.underlying_shares: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
June 22, 2021 Filed Jun 23, 2021 16:41 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	PurchaseCommon Stock	750,000	$20.00	$15,000,000.00	Disclosure SEC source: 0001209191-21-042752 · doc4.xml · nonDerivative · entry 3 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,675,838 F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
June 22, 2021 Filed Jun 23, 2021 16:41 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	ConversionCommon Stock	1,535,238	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-042752 · doc4.xml · nonDerivative · entry 2 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,925,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
June 22, 2021 Filed Jun 23, 2021 16:41 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	ConversionCommon Stock	10,390,600	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-042752 · doc4.xml · nonDerivative · entry 1 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,390,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date. F2 · ownership.direct: The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V. Read SEC document
December 03, 2020 Filed Dec 3, 2020 16:55 UTC	Elanco Animal Health Inc ELAN · Entity 3457	SaleCommon Stock	54,500,000	$29.84	$1,626,367,200.00	Disclosure SEC source: 0000899243-20-032676 · doc4.xml · nonDerivative · entry 1 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer World Investments B.V. · CIK 0001820027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,446,429 F1 · shares: Pursuant to an underwriting agreement, dated November 30, 2020, and in connection with the registered public offering of shares of common stock of the Issuer ("Common Stock") pursuant to the prospectus, dated as of January 21, 2020 and filed with the U.S. Securities and Exchange Commission (the "SEC") on January 21, 2020 and the prospectus supplement dated as of November 30, 2020 and filed with the SEC on December 2, 2020, which offering settled on December 3, 2020, Bayer World Investments B.V. sold 54,500,000 shares of Common Stock. F2 · ownership.nature: The securities reported as sold were, and those reported as held after the transaction are, held directly by Bayer World Investments B.V., which is an indirect wholly owned subsidiary of Bayer Aktiengesellschaft. Bayer Aktiengesellschaft may be deemed to beneficially own the shares of the Issuer's Common Stock beneficially owned by Bayer World Investments B.V. Read SEC document
January 05, 2018 Filed Jan 30, 2018 14:21 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Shares	527,472	$22.75	$11,999,988.00	Disclosure SEC source: 0000029905-18-000006 · edgar.xml · nonDerivative · entry 1 BAYER AKTIENGESELLSCHAFT · CIK 0001144145 · 10% owner Bayer Global Investments B.V. · CIK 0001685417 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By subsidiary Disclosed balance after: 5,632,802 F1 · ownership.nature: Represents purchase by Bayer Global Investments B.V. ("Bayer BV"). Bayer BV is the Direct Owner of 5,632,802 common shares of CRISPR Therapeutics AG ("CRISR"). This Form 4 is a joint filing of Bayer BV and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer BV is the Direct Owner. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.